Isofol Medical AB (publ) (ISOFOL.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 1.09 (-8.25%) as of
Key statistics
- Market cap
- 349.34M
- Forward P/E
- -21.80
- EPS (TTM)
- -0.2000
- Dividend yield
- 0.00%
- 52-week range
- 0.5515 – 1.2500
- Beta
- 1.02
- Profit margin
- 0.00%
- Analyst target
- SEK 1.70
- Volume
- 2.61M
About Isofol Medical AB (publ)
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Gothenburg, Sweden
- Employees
- 7
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.